Pharma Focus Europe

Kanvas Biosciences Enhances Operations Through Acquisition of Federation Bio Assets to Advance Research, Development, and Production of Microbiome-based Therapeutics

Thursday, October 12, 2023

Kanvas Biosciences, a company specializing in microbiome mapping technology, has announced its acquisition of two active therapeutics programs, a microbial library, and intellectual property from Federation Bio, a manufacturer of live biotherapeutics products (LBPs). This acquisition represents a significant shift for Kanvas Biosciences, as it transitions from a technology-focused company with a spatial biology platform to a comprehensive therapeutics company with active clinical programs. It also includes the establishment of a new cell banking facility in South San Francisco. The deal also brings on board Lee Swem, formerly Chief Science Officer at Federation Bio, as Kanvas Biosciences' Chief Development Officer, further expanding the company's leadership and West Coast presence.

Matthew Cheng, the co-founder and CEO of Kanvas Biosciences, expressed enthusiasm for the acquisition, highlighting the potential to expedite the manufacturing and clinical investigation of complex microbial consortia. Cheng stressed that this approach would allow the company to positively impact patients' lives more rapidly compared to the lengthy process of building manufacturing capabilities from scratch. He also noted the productive history of collaboration between Kanvas Biosciences and Federation Bio on microbiome projects and their anticipation of what the combined platform technologies can achieve.

The microbiome plays a crucial role in human health, either improving or exacerbating various diseases, including autoimmune conditions, metabolic disorders, gastrointestinal issues, and cancer. While microbial therapies have proven effective for conditions caused by microbial dysbiosis, there is a lack of tools for understanding the biology of and treatments for other microbiome-related diseases. Kanvas Biosciences aims to develop superior microbial therapies with different mechanisms of action, capable of working synergistically and safely with existing treatments to enhance outcomes for such diseases. Additionally, the company's highly advanced spatial imaging technology, originally published in the journal Nature, provides pharmaceutical, biotech, and healthcare organizations with a unique tool for gaining insights into microbiome-host interactions, akin to a Google Maps-like experience. This technology also offers detailed information about the engraftment locations and metabolic functions of LBPs. With novel spatial biology and manufacturing platforms, Kanvas Biosciences is poised to be a pioneering company capable of leveraging complex microbial therapies with hundreds of members simultaneously.

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva